AbbVie (NYSE: ABBV) will announce its third-quarter 2024 financial results on Wednesday, October 30, 2024, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 ...

AbbVie (ABBV) stock price has done well this year as it surged to a record high of $200. It has jumped by more than 32% this ...

Office of Prescription Drug Promotion (OPDP) recently sent an Untitled Letter to AbbVie, Inc., regarding a television ad starring Serena Williams for its migraine medicine Ubrelvy. According to the ...

Given its better valuation, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pick than its peer – ...

AbbVie's strong entrenchment in the aesthetics business (gained through the Allergan acquisition) sets up very long product cycles for several key assets like Botox based on strong brand power and ...

AbbVie’s revenue growth has been buoyed by its Allergan acquisition in 2020. The company is best known for its blockbuster drug – Humira – used to treat rheumatoid arthritis and Crohn’s ...

AbbVie's management knew this was coming and did a masterful job of diversifying the portfolio, starting with the 2019 acquisition of Allergan. Drugs like Botox, Juvederm, Vraylar, Linzess ...

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from ...

Given its better valuation, we believe that Pfizer stock (NYSE: PFE) is currently a better pick than its industry peer – AbbVie stock (NYSE:ABBV). PFE stock trades at a much lower multiple of 11x ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...

John Paulson’s hedge fund has good reason to want Allergan to buy Shire. AbbVie just walked away from its deal for Shire. That sent Shire’s shares tumbling, leading to substantial paper losses ...